Genenta Science S.p.A. (SAEN) stock
SAENNasdaqBiological Products, (No Diagnostic Substances)
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.58+0.00 (+0.85%)
Close on Nov 18, 2026Market cap $13.64MP/E –Yield –
Genenta Science S.p.A. r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €2.70M, down 43.9% from the year before. The highest annual figure on record is €6.47M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €2.70M | -43.9% |
| FY2024 | Dec 31, 2024 | €4.81M | -25.7% |
| FY2023 | Dec 31, 2023 | €6.47M | +21.3% |
| FY2022 | Dec 31, 2022 | €5.34M | +57.5% |
| FY2021 | Dec 31, 2021 | €3.39M | -27.7% |
| FY2020 | Dec 31, 2020 | €4.69M | +26.6% |
| FY2019 | Dec 31, 2019 | €3.70M | – |
See a number that looks wrong?